Is Verastem going out of business?

Verastem, Inc. (VSTM) Fundamentals

A quick summary of the latest filed figures while the full analysis loads.

Verastem, Inc. (VSTM) scores 27 out of 100 on fundamentals, Distressed / Caution, based on SEC filing data.

Leading signal: Shares dilution YoY: 64.82% (YoY)

Five questions, kept separate

Survival - Critical

4-7 mo of estimated runway from 2026-06-30, based on $136M of cash and short-term investments against $286M of annual burn. Adjusted shares outstanding increased 64.8% over the comparison year.

Business quality - Pre-commercial

Operating margins cannot grade a pipeline; Survival and clinical evidence remain the relevant lenses here.

Trajectory - Clinical progress unavailable

Fundamentals can show funding and burn, but not whether the clinical pipeline is advancing.

Valuation - Reasonable

28.3% net-cash backing support a reasonable pre-commercial Valuation assessment.

Event risk - Critical event risk

Going-Concern Warning is the decisive filing event; one adverse event family is active. It appears across 2 scanned filings. Favorable events are shown separately and do not offset adverse risk.

What the rules read

• Shares dilution YoY: 64.82% (YoY)
• ROIC: 189.71%
• Interest coverage: -108.3x
• Filing event risk: Going-Concern Warning (-8 pts)
• Revenue CAGR (3Y): 128.36%
• Debt / Equity: No financial debt (debt-free)
• Revenue growth YoY: 1775.43% (YoY) - Growth from a low base; sustainability uncertain.
• Return on Assets: -101.43%
• Revenue per Asset Efficiency: 136.79% QoQ (Strong monetization)
• Revenue Quality: Quality concerns (DSO +310d, Rev +1775%)
• Debt Maturity Runway: 0% long-term (Near-term refinancing risk)
• Price / Sales: 23.3x (see Valuation)

Read from filings through 2026-08-07.

Price as of 2026-09-09.